(Q41139783)

27 September 2017

1 reference

title

Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders (English)

1 reference

27 September 2017

1 reference

C J Dunn

1

1 reference

27 September 2017

E M Sorkin

series ordinal

2

1 reference

27 September 2017

publication date

1 August 1996

1 reference

27 September 2017

1 reference

27 September 2017

volume

52

1 reference

27 September 2017

issue

2

1 reference

27 September 2017

page(s)

276-305

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199652020-00011

27 September 2017

exact match

0 references

cites work

Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin

1 reference

12 December 2020

Severe thrombocytopenia with pulmonary embolism and consumption coagulopathy during treatment with tedelparin

1 reference

12 December 2020

Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism

1 reference

12 December 2020

Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients

1 reference

12 December 2020

Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations

1 reference

12 December 2020

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

1 reference

12 December 2020

A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin).

1 reference

12 December 2020

Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoid

1 reference

12 December 2020

Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin.

1 reference

12 December 2020

Effects of long-term therapy with either heparin or low-molecular-weight heparin on serum lipid levels. A prospective study

1 reference

12 December 2020

Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group

1 reference

12 December 2020

The heparin-mobilisable pool of platelet factor 4: a comparison of intravenous and subcutaneous heparin and Kabi heparin fragment 2165.

1 reference

12 December 2020

A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis.

1 reference

12 December 2020

Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).

1 reference

12 December 2020

Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery

1 reference

12 December 2020

Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

1 reference

12 December 2020

Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg

1 reference

12 December 2020

Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications

1 reference

12 December 2020

The high-risk unstable angina patient. An approach to treatment

1 reference

12 December 2020

Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis

1 reference

12 December 2020

Physiological changes due to age. Implications for the prevention and treatment of thrombosis in older patients

1 reference

12 December 2020

Prophylaxis of postoperative deep vein thrombosis in general surgery: experiences with Fragmin

1 reference

12 December 2020

Treatment of deep venous thrombosis. Comparative study of a low molecular weight heparin fragment (Fragmin) by the subcutaneous route and standard heparin by the continuous intravenous route. A multicenter study

1 reference

12 December 2020

Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4

1 reference

12 December 2020

The adequacy of fragmin as a single bolus dose with reused dialyzers

1 reference

12 December 2020

Reduced lipid concentrations during four years of dialysis with low molecular weight heparin

1 reference

12 December 2020

[Effectiveness of low molecular weight heparin (Fragmin) in the prevention of thromboembolism in internal medicine patients. A randomized double-blind study]

1 reference

12 December 2020

Low-molecular-weight heparin.

1 reference

12 December 2020

Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis

1 reference

12 December 2020

LMW heparin: relationship between antithrombotic and anticoagulant effects

1 reference

12 December 2020

The cost-effectiveness of prevention of post-operative thromboembolism.

1 reference

12 December 2020

Human pharmacological studies of a defined low molecular weight heparin fraction (Fragmin) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin).

1 reference

12 December 2020

Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group

1 reference

12 December 2020

Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study

1 reference

12 December 2020

Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan

1 reference

12 December 2020

Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin

1 reference

12 December 2020

Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers

1 reference

12 December 2020

[Severe thrombopenia appearing in treatment with tedelparin]

1 reference

12 December 2020

Heparin-associated thrombocytopenia: the antibody is not heparin specific

1 reference

12 December 2020

Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery

1 reference

12 December 2020

In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets

1 reference

12 December 2020

Heparins, coumarin, and bone density

1 reference

12 December 2020

Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

1 reference

12 December 2020

Molecular and cellular biology of blood coagulation

1 reference

12 December 2020

Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).

1 reference

12 December 2020

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

1 reference

12 December 2020

Low molecular weight heparins. An objective overview

1 reference

12 December 2020

A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin

1 reference

12 December 2020

[Biological criteria for the evaluation of prophylactic treatment with a low molecular weight heparin (Kabi 2165)]

1 reference

12 December 2020

Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)

1 reference

12 December 2020

A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia

1 reference

12 December 2020

A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment.

1 reference

12 December 2020

Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group

1 reference

12 December 2020

Plasma lipolytic activity after subcutaneous administration of heparin and a low molecular weight heparin fragment

1 reference

12 December 2020

Absence of transplacental passage of fragmin (Kabi) during the second and the third trimesters of pregnancy

1 reference

12 December 2020

Low molecular weight heparin use in haemodialysis: a comparison with standard heparin and a cost-analysis

1 reference

12 December 2020

Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis

1 reference

12 December 2020

Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin

1 reference

12 December 2020

The influence of surgical trauma on factor XaI and IIaI activity and heparin concentration after a single dose of low-molecular-weight heparin

1 reference

12 December 2020

Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group

1 reference

12 December 2020

Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis.

1 reference

12 December 2020

Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery

1 reference

12 December 2020

Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties

1 reference

12 December 2020

The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study

1 reference

12 December 2020

Thrombosis prophylaxis with low molecular weight heparin in total hip replacement

1 reference

12 December 2020

Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome?

1 reference

12 December 2020

Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin

1 reference

12 December 2020

A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers

1 reference

12 December 2020

Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins

1 reference

12 December 2020

A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis

1 reference

12 December 2020

Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution

1 reference

12 December 2020

Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation

1 reference

12 December 2020

Prophylaxis for Venous Thromboembolism in Hip Fracture Surgery

1 reference

12 December 2020

A cross-over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuronan

1 reference

12 December 2020

Treatment of venous thromboembolism with low molecular weight heparins

1 reference

12 December 2020

Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty

1 reference

12 December 2020

Heparin‐induced skin reaction with low molecular‐weight heparin

1 reference

12 December 2020

Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).

1 reference

12 December 2020

Low molecular weight heparin: a critical analysis of clinical trials

1 reference

12 December 2020

Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin

1 reference

12 December 2020

[Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery]

1 reference

12 December 2020

Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery

1 reference

12 December 2020

Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin).

1 reference

12 December 2020

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

1 reference

12 December 2020

A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin

1 reference

12 December 2020

Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)

1 reference

12 December 2020

Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group

1 reference

12 December 2020

Delayed cutaneous reaction to unfractionated heparin, low molecular weight heparin and danaparoid

1 reference

12 December 2020

Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration

1 reference

12 December 2020

[Comparison of the efficacy and tolerance of Kabi 2165 and standard heparin in the prevention of deep venous thrombosis in total hip prosthesis]

1 reference

12 December 2020

Prevention of thromboembolism in hysterectomies with low molecular weight heparin Fragmin

1 reference

12 December 2020

Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. A placebo controlled study

1 reference

12 December 2020

Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis

1 reference

12 December 2020

Biological modifications induced by 3 low molecular weight heparins, PK 10169, Kabi 2165 and CY 216, compared to unfractionated heparin injected subcutaneously in healthy subjects in general surgery and in aged subjects in internal medicine

1 reference

12 December 2020

Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance

1 reference

12 December 2020

Skin reaction with low molecular weight heparins.

1 reference

12 December 2020

A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial

1 reference

12 December 2020

Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics

1 reference

12 December 2020

Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects

1 reference

12 December 2020

Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients

1 reference

12 December 2020

How long after surgery does the risk of thromboembolism persist?

1 reference

12 December 2020

Lipolytic effect of low-molecular-weight-heparin (Fragmin) and heparin/dihydroergotamine in thromboprophylactic doses during total hip replacement

1 reference

12 December 2020

Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin

1 reference

12 December 2020

Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis

1 reference

12 December 2020

Lipoprotein lipase, hepatic lipase and plasma lipolytic activity. Effects of heparin and a low molecular weight heparin fragment (Fragmin).

1 reference

12 December 2020

Low molecular weight heparin in prevention of perioperative thrombosis

1 reference

12 December 2020

Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.

1 reference

12 December 2020

10.2165/00003495-199652020-00011

Identifiers

DOI

1 reference

Dimensions Publication ID

27 September 2017

1002733514

0 references

1 reference